
Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.
ZNF432 (zinc finger protein 432) encodes a zinc finger protein with damaged DNA-binding and protein-macromolecule adaptor activities. It participates in the cellular DNA damage response and is localized in the nucleoplasm. Through its DNA- and protein-binding properties, ZNF432 may contribute to coordination of molecular responses to damaged DNA, although its specific targets and mechanisms remain incompletely characterized.
HT-29 is a human colorectal adenocarcinoma cell line established from a primary colon tumor of a 44-year-old female patient in 1964. The cells can undergo differentiation into mature goblet-like cells and produce mucin-secreting subclones, such as HT29-MTX, which exhibit characteristics of intestinal epithelial differentiation, including tight junction formation and mucus layer production. HT-29 is widely used as a model for studying colorectal cancer biology, intestinal epithelial differentiation, barrier function, and drug or nanoparticle transport.
Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.

Targeted knockout region: EExon 3
Reference Transcript: NM_014650
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use





Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours.
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?